Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-01-13
1998-03-24
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514291, 514292, 514826, A61K 3144
Patent
active
057313199
ABSTRACT:
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
REFERENCES:
patent: 4659716 (1987-04-01), Villani et al.
patent: 5019591 (1991-05-01), Gardner et al.
patent: 5089496 (1992-02-01), Piwinski et al.
Babe et al., "Histamine, Bradykinin, and Their Antagonists" Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 581-593 and 598-599 (1996).
McCue, J., "Safety of Antihistamines in the Treatment of Allergic Rhinitis in Elderly Patients" Arch Fam Med 5:464-468 (1996).
Anderson et al., "Adverse Drug Interactions Clinically Important for the Dermatologist" Arch. Dermatol. 131:468-473, (1995).
Peggs et al., "Antihistamines: The Old and The New" American Family Physician 52(2):593-600 (1995).
Berthon et al., "In Vitro Inhibition, by Loratadine and Descarboxyethoxloratadine, of Histamine Release from Human Basophils, and of Histamine Release and Intracellular Calcium Fluxes in Rat Basophilic Leukemia Cells (RBL-2H3)" Biochemical Pharmacology 47:(5), pp. 789-794 (1994).
Brandes et al., "Enhanced Cancer Growth in Mice Administered Daily Human-Equivalent Doses of Some H.sub.1 -Antihistamines: Predictive In Vitro Correlates" J. Nat. Can. Inst. Reports 86:(10), pp. 770-775 (1994).
Kleine-Tebbe et al., "Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H.sub.1 antagonist, desethoxycarbonyl-loratadine" J. Allergy Clin. Immunol. 93:(2), pp. 494-500 (1994).
Miadonna et al., "Inhibitory Effect of the H.sub.1 Antagonist Loratadine on Histamine Release from Human Basophils" Int. Arch. Allergy Immunol. (105), pp. 12-17 (1994).
Simons, F.E.R., "H.sub.1 -Receptor Antagonists Comparative Tolerability and Safety" Drug Safety 10(5):350-380 (1994).
Zhong et al., "HPLC-Bestimmung Von Loratadin und seinem aktiven Metaboliten Descarboethoxyloratadin in Humanplasma" Pharmazie (49) H.10, pp. 736-739 (1994) (English abstract attached).
Quercia et al., "Focus on loratadine: A new second-generation nonsedating H.sub.1 -receptor antagonist" Hosp. Formul. (28), pp. 137-149, 153 (1993).
Lavrijsen et al., "The Interaction of Ketoconazole, Itraconazole and Erythromycin With the In Vitro Metabolism of Antihistamines in Human Liver Microsomes" Abstract 1233 Eur. J. Allergy Clin. Immunol. 48, Suppl. 16, 34 (1993).
Roman et al., "Loratadine A Review of Recent Findings in Pharmacology, Pharmacokinetics, Efficacy, and Safety, with a Look at Its Use in Combination with Pseudoephedrine" Clinical Reviews in Allergy 11:89-110 (1993).
Van Peer et al., "Ketoconazole Inhibits Loratadine Metabolism in Man" Abstract 1234 Eur. J. Allergy Clin. Immunol. 48, Suppl. 16, 34 (1993).
Product Insert CR-318/17597400 7/93 Schering Corporation (1992,1993).
Brandes et al., "Stimulation of Malignant Growth in Rodents by Antidepressant Drugs at Clinically Relevant Doses" Cancer Research (52), pp. 3796-3800 (1992).
Kaliner, M., "Nonsedating Antihistamines: Pharmacology, Clinical Efficacy and Adverse Effects" American Family Physician 45(3):1337-1342 (1992).
Knowles, "Astemizole and Terfenadine--Induced Cardiovascular Effects" Canadian J. Hosp. Pharm. 45:(1):33, 37 (1992).
Parkinson et al., "Evaluation of Loratadine as an Inducer of Liver Microsomal Cytochrome P450 In Rats and Mice" Biochemical Pharmacology 43:(10):2169-2180 (1992).
Van Cauwenberge, P., "New Data on the Safety of Loratadine" Drug Invest. 4(4):283-291 (1992).
Barnett et al., "Pharmacology of Non-Sedating H.sub.1 Antihistamines" New Perspectives in Histamine Research pp. 181-196 (1991).
"Antihistamines " Chapter 16 Side Effects of Drugs Annual 14, pp. 135-138 Elsevier Science Publishers (1990).
Gengo, F.M, "Delimma: Antihistamine Selection: Use vs. Side Effects" U.S. Pharmacist pp. 59-72, 92 (1990).
Clissold et al., "Loratadine A Preliminary Review of its Pharmacodynamic Properties and Therapeutic Efficacy" Drugs 37, pp. 42-57 (1989).
"Antihistamines" Chapter 16 Side Effects of Drugs Annual 12, pp. 142-143 Elsevier Science Publishers (1988).
Simons et al., "Astemizole--Induced Torsades de Pointes" Lancet p. 624 (Sep. 10, 1988).
Temple et al., "Loratadine, an Antihistamine, Blocks antigen- and Ionophore--Induced Leukotriene Release From Human Lung In Vitro" Prostaglandins 35:(4), pp. 549-554 (1988).
Hilbert et al., "Pharmacokinetics and Dose Proportionality of Loratadine" J. Clin. Pharmacol. (27), pp. 694-698 (1987).
Craft, "Torsade de Pointes After Astemizole Overdose" British Med. J. (292), p. 660 (1986).
Barnett et al., "Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine" Agents and Actions 14:(5/6), pp. 590-597 (1984).
Wood, "Antimotion Sickness and Antiemetic Drugs" Drugs (17), 17 pp. 471-479 (1979).
Cohen et al., "Meclizine and Placebo in Treating Vertigo of Vestibular Origion" Arch. Neurol. (27), pp. 129-135 (1972).
Aberg A. K. Gunnar
McCullough John R.
Smith Emil R.
Criares Theodore J.
Sepracor Inc.
University of Massachusetts
LandOfFree
Methods for treating disorders using descarboethoxyloratadine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating disorders using descarboethoxyloratadine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating disorders using descarboethoxyloratadine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2289169